Neurology · MigraineTrial Updateclinicalmid-term

AbbVie initiates trial for ubrogepant in menstrual migraine treatment

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AbbVie8 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 6:31:53 AM

Assessment confidence: 63% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of AbbVie's trial for ubrogepant in treating menstrual migraine is significant as it targets a niche yet impactful segment of the migraine treatment market. Success in this trial could bolster AbbVie's competitive positioning and expand its portfolio in neurology. Regulatory context from MHRA (ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly) supports the near-term read. Assessment grounded in 17 ranked evidence items (7 high-relevance).

Strategic Assessment

Success in this trial could enhance AbbVie's portfolio in migraine therapies and provide a competitive edge against existing treatments. The strongest clinical anchor is Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine (ClinicalTrials.gov), entity match (abbvie). In Neurology · Migraine, 5 regulatory and 1 competitive items passed relevance filtering for AbbVie.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). This trial positions AbbVie in the competitive landscape of migraine treatments, particularly for menstrual migraine, which is a niche but significant market.

Regulatory Outlook

Regulatory risk is concentrated around ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly (MHRA). Regulatory pathway relevance (nda). Relevant agencies in corpus: MHRA, FDA. The trial's outcomes will be critical for regulatory approval processes, influencing labeling and market entry strategies for ubrogepant in the context of menstrual migraine treatment.

Key Risks

Elevated medium regulatory exposure for AbbVie could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, ubrogepant could capture market share in the menstrual migraine segment, potentially leading to increased revenue for AbbVie, especially given the unmet needs in this area.
Upside for AbbVie may improve if Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. (PubMed) delivers favorable follow-through.
Upside for AbbVie may improve if Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) (ClinicalTrials.gov) delivers favorable follow-through.
Success in this trial could enhance AbbVie's portfolio in migraine therapies and provide a competitive edge against existing treatments.

What Would Change This Assessment

This becomes more urgent if Monitor trial enrollment progress, interim results, and any announcements regarding efficacy and safety outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly
MHRAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — UBROGEPANT (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves First Single-Dose Generic Treatment for Influenza
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Lower dose needle-free allergy treatment approved for younger children
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Over-The-Counter (OTC) Heartburn Treatment
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
ClinicalTrials.govhigh relevance
Entity match (abbvie)
FDA document
View source
Trial of an Online Spanish Pivotal Response Treatment Training in Autism Spectrum Disorder
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AbbVie

Commercial impact

medium

If successful, ubrogepant could capture market share in the menstrual migraine segment, potentially leading to increased revenue for AbbVie, especially given the unmet needs in this area.

Regulatory impact

medium

The trial's outcomes will be critical for regulatory approval processes, influencing labeling and market entry strategies for ubrogepant in the context of menstrual migraine treatment.

What to watch

Monitor trial enrollment progress, interim results, and any announcements regarding efficacy and safety outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.